nyuuzyou/wikis huggingface dataset:
Interferon alfa-2a (Roferon-A)

==General information==
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.Interferon alfa-2a (Roferon-A) package insertInterferon alfa-2a (Roferon-A) package insert (locally hosted backup)
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is established (work in progress)==
*Chronic myeloid leukemia
*Hairy cell leukemia
*Renal cell carcinoma
==Diseases for which it is used==
*Kaposi sarcoma
*Neuroendocrine tumor
*Cutaneous squamous cell carcinoma
==Diseases for which it was used==
*Follicular lymphoma
*Melanoma
*Multiple myeloma
==Patient drug information==
*Interferon alfa-2a (Roferon-A) package insert
*Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)
==History of changes in FDA indication==
*1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with hairy cell leukemia (Based on N2752)
*Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis). (Based on DM 84-38 & MI400)
==Also known as==
*Brand name: Laroferon, Roferon-A
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Interferon alfas
Category:Chronic myeloid leukemia medications
Category:Hairy cell leukemia medications
Category:Kaposi sarcoma medications
Category:Neuroendocrine tumor medications
Category:Renal_cell_carcinoma medications
Category:Cutaneous squamous cell carcinoma medications
Category:Follicular lymphoma medications (historic)
Category:Melanoma medications (historic)
Category:Multiple myeloma medications (historic)
Category:FDA approved in 1986
Interferon alfa-2c (Berofor)

==General information==
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it was used==
*Renal cell carcinoma
==Also known as==
*Brand name: Berofor
Category:Drugs
Category:Subcutaneous medications
Category:Interferon alfas
Category:Renal cell carcinoma medications (historic)
Category:Stub
Interferon alfa-n1 (Wellferon)

==General information==
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Chronic myeloid leukemia
==Also known as==
*Brand name: Wellferon
Category:Drugs
Category:Intramuscular medications
Category:Subcutaneous medications
Category:Interferon alfas
Category:Chronic myeloid leukemia medications
Category:Stub
Interferon gamma-1a (Imunomax-γ)

==General information==
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.
==Diseases for which it is used==
*Cutaneous T-cell lymphoma
==History of changes in PMDA indication==
*2014-05-23: New additional indications and a new dosage for the treatment of mycosis fungoides and Sézary syndrome.
==Also known as==
*Brand name: Imunomax-γ
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Cutaneous T-cell lymphoma medications
Category:Interferon gammas
Category:Stub
Interferon gamma-1b (Actimmune)

==General information==
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it was used==
*Ovarian cancer
==History of changes in FDA indication==
* 1999-02-25: Initial FDA approval
== Patient Drug Information==
*Interferon gamma-1b (Actimmune) Package InsertInterferon gamma-1b (Actimmune) Package Insert
==Also known as==
*Brand name: Actimmune
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Interferon gammas
Category:Ovarian cancer medications (historic)
Category:FDA approved in 1999
Intravenous immunoglobulin (IVIG)

With the exception of ITP, IVIG is used primarily to prevent infections caused by secondary hypogammaglobulinemia in the hematology/oncology domains.
==Diseases for which it used==
*Immune thrombocytopenia (ITP)
==Also known as==
*Generic name: IVIG
*Brand names: Flebogamma, Gammagard, Gamunex, Octagam, Privigen
Category:Fractionated plasma products
Category:Intravenous medications
Category:Immune thrombocytopenia medications
Category:Supportive medications
Iobenguane I 131 (Azedra)

==General information==
Radioactive MIBG
==Diseases for which it was used==
*Pheochromocytoma
==History of changes in FDA indication==
*2018-07-30: Initial approval for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. (Based on MIP-IB12B)
==History of changes in PMDA indication==
*2021-09-27: Newly indicated for the treatment of unresectable MIBG-positive pheochromocytoma/paraganglioma.
==Also known as==
*Generic names: 131I-Metaiodobenzylguanidine, 131I-MIBG, [131I]MIBG, m-[131I]iodobenzylguanidine
*Brand name: Azedra, PheoMIBG-I 131, Raiatt MIBG-I 131
Category:Drugs
Category:Radiotherapy medications
Category:Intravenous medications
Category:Pheochromocytoma medications
Category:FDA approved in 2018
Category:PMDA approved in 2021
Category:Stub
Iodine I 131 apamistamab (Iomab-B)

==Mechanism of action==
From the NCI Drug Dictionary: A radioimmunoconjugate consisting of BC8, a murine IgG1 anti-CD45 monoclonal antibody labeled with iodine 131 (I-131), with radioimmunotherapeutic properties. Using monoclonal antibody BC8 as a carrier for I-131 results in the targeted destruction of cells expressing CD45.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Acute myeloid leukemia===
#SIERRA: Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco JJ, Jamieson K, Silverman M, Van Besien K, Schuster M, Law AD, Larkin K, Pandit-Taskar N, Rowley SD, Munshi P, Cook R, Levy MY, Lazarus HM, Sandmaier BM, Pagel JM, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol. 2025 Jan 10;43(2):201-213. Epub 2024 Sep 19. link to original article link to PMC article EuroPMC NCT02665065
==Also known as==
*Brand name: Iomab-B
Category:Drugs
Category:Intravenous medications
Category:Anti-CD45 radioimmunoconjugates
Category:Radiotherapy medications
Category:Acute myeloid leukemia medications (investigational)
Category:Investigational drugs
Ipatasertib (GDC-0068)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.
==Preliminary data==
===Breast cancer, triple negative===
# LOTUS: Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1360-1372. Epub 2017 Aug 8. link to original article link to PMC article EuroPMC NCT02162719
===Prostate cancer===
# IPATential150: Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F, Atduev V, Buchschacher GL Jr, Gafanov R, Corrales L, Borre M, Stroyakovskiy D, Alves GV, Bournakis E, Puente J, Harle-Yge ML, Gallo J, Chen G, Hanover J, Wongchenko MJ, Garcia J, de Bono JS. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021 Jul 10;398(10295):131-142. link to original article EuroPMC NCT03072238
==Also known as==
*Code names: GDC-0068, RG-7440
Category:Drugs
Category:Oral medications
Category:AKT1 inhibitors
Category:Breast cancer medications (investigational)
Category:Prostate cancer medications (investigational)
Category:Investigational drugs
Iptacopan (Fabhalta)

==General information==
Class/mechanism: orally bioavailable, highly potent and highly selective factor B inhibitor. Blocks the alternative pathway of complement upstream of both CD55 and CD59. Iptacopan is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH).
Route: oral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, UpToDate (courtesy of Lexicomp)
==Toxicity management==
*Link to REMS program
==Diseases for which it is established==
*Paroxysmal nocturnal hemoglobinuria
==History of changes in FDA indication==
*2023-12-05: Approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). (Based on APPLY-PNH & APPOINT-PNH)
==Also known as==
*Code name: LNP-023
*Brand name: Fabhalta
Category:Drugs
Category:Oral medications
Category:Factor B inhibitors
Category:Paroxysmal nocturnal hemoglobinuria medications
Category:REMS program
Category:FDA approved in 2023
Irinotecan liposome (Onivyde)

==General information==
Class/mechanism: Topoisomerase I inhibitor with irinotecan contained within a liposomal sphere. Irinotecan interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death. In mouse models, 5 times lower doses of liposomal irinotecan were able to achieve similar intratumoral exposure levels of SN-38 as compared to irinotecan HCl.Irinotecan liposome (Onivyde) package insert Irinotecan liposome (Onivyde) package insert (locally hosted backup)Onivyde manufacturer's websiteMerrimack Pharmaceuticals's MM-398 website
Route: IV
Extravasation: no information available
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Esophageal cancer
**Esophageal adenocarcinoma
*Gastric cancer
*Pancreatic cancer 
==Patient drug information==
*Patient counseling information is available in the Irinotecan liposome (Onivyde) package insert 
==History of changes in FDA indication==
*2015-10-22: Approved in combination with fluorouracil (5FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas whose disease has progressed following gemcitabine-based therapy. (Based on NAPOLI-1)
*2024-02-13: Approved with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma. (Based on NAPOLI 3)
==History of changes in EMA indication==
*2016-10-14: Initial authorization
==History of changes in Health Canada indication==
*2017-08-09: Initial notice of compliance (unclear details)
==History of changes in PMDA indication==
*2020-03-25: Newly indicated for the treatment of unresectable pancreatic cancer that has progressed after cancer chemotherapy.
==Also known as==
*Code names: MM-398, PEP-02
*Brand name: Onivyde, Onivyde pegylated liposomal
==References==
Category:Drugs
Category:Intravenous medications
Category:Liposomal chemotherapy
Category:Topoisomerase I inhibitors
Category:Esophageal adenocarcinoma medications
Category:Esophageal cancer medications 
Category:Gastric cancer medications 
Category:Pancreatic cancer medications 
Category:FDA approved in 2015
Category:EMA approved in 2016
Category:Health Canada approved in 2017
Category:PMDA approved in 2020
Iron dextran (INFeD)

==General information==
Class/mechanism: Iron, which is needed for various biologic processes, including synthesis of hemoglobin and multiple enzymatic processes.Iron dextran (INFeD) package insert Iron dextran (INFeD) package insert (locally hosted backup)INFeD manufacturer's website
Route: IV, IM
Extravasation: no information
*1 mL of INFeD provides 50 mg of elemental iron
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Iron dextran (INFeD) patient drug information (UpToDate)Iron dextran (INFeD) patient drug information (UpToDate)
==Also known as==
*Brand names: Dexferrum, DextraCare, Ferrodex, Imferon, INFeD, Irondex, Saferon, Uniferon
==References==
Category:Drugs
Category:Intravenous medications
Category:Intramuscular medications
Category:Hematology medications
Category:Iron replacement
Category:FDA approved in 1957
Iron sucrose (Venofer)

==General information==
Class/mechanism: Iron, which is needed for various biologic processes, including synthesis of hemoglobin and multiple enzymatic processes.Iron sucrose (Venofer) package insert Iron sucrose (Venofer) package insert (locally hosted backup)Venofer manufacturer's website
Route: IV
Extravasation: no information
*1 mL of Venofer provides 20 mg of elemental iron
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Brief patient counseling information can be found in the Iron sucrose (Venofer) package insert
*Iron sucrose (Venofer) patient drug information (UpToDate)Iron sucrose (Venofer) patient drug information (UpToDate)
==History of changes in FDA indication==
*2000-11-06: Approved for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD).
==Also known as==
*Brand name: Venofer
==References==
Category:Drugs
Category:Intravenous medications
Category:Hematology medications
Category:Iron replacement
Category:FDA approved in 2000
Isatuximab (Sarclisa)

==General information==
Class/mechanism from NCI Drug Dictionary: A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Multiple myeloma
==History of changes in FDA indication==
*2020-03-02: Approved in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (Based on ICARIA-MM)
*2021-03-31: Approved in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. (Based on IKEMA)
*2024-09-20: Approved with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). (Based on IMROZ)
==History of changes in EMA indication==
*2020-05-30: Initial authorization
==History of changes in Health Canada indication==
*2020-04-29: Initial notice of compliance
==History of changes in PMDA indication==
*2020-06-29: Newly indicated for the treatment of relapsed or refractory multiple myeloma.
== Patient Drug Information==
*Isatuximab (Sarclisa) Package InsertIsatuximab (Sarclisa) Package Insert
==Also known as==
*Code name: SAR-650984
*Generic name: isatuximab-irfc
*Brand name: Sarclisa
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-CD38 antibodies
Category:Multiple myeloma medications
Category:EMA approved in 2020
Category:FDA approved in 2020
Category:Health Canada approved in 2020
Category:PMDA approved in 2020
Isotretinoin (Accutane)

==Mechanism of action==
From the NCI Drug Dictionary: A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.
==Diseases for which it is used==
*Cutaneous squamous cell carcinoma
*Neuroblastoma
==Diseases for which it was used==
*Renal cell carcinoma
== Patient Drug Information==
*Isotretinoin (Accutane) Package InsertIsotretinoin (Accutane) Package Insert
==History of changes in EMA indication==
*1982-05-07: EURD
==Also known as==
*Code name: Ro 4-3780
*Generic names: 13-cis-retinoic acid, 13-cis-vitamin A acid, 13-CRA, cis-retinoic acid, isotretinoinum, neovitamin A
*Brand names: Absorica, Accure, Accutane, Amnesteem, Cistane, Claravis, Isotrex, Isotrexin, Myorisan, Oratane, Roaccutan, Roaccutane, Roacutan, Sotret, Zenatane
==References==
Category:Drugs
Category:Oral medications
Category:Retinoids
Category:Neuroblastoma medications
Category:Cutaneous squamous cell carcinoma medications
Category:Renal cell carcinoma medications (historic)
Category:FDA approved in 1982
Category:EMA approved in 1982
Ivonescimab (Akeso)

==Mechanism of action==
From the NCI Drug Dictionary: A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, ivonescimab simultaneously targets and binds to both PD-1 expressed on certain T cells and VEGF expressed on tumor cells. The binding of ivonescimab to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of ivonescimab to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis.
==Diseases for which it is used==
*EGFRm NSCLC
==History of changes in NMPA indication==
*2024-05-24: Approved in combination with pemetrexed and carboplatin, for the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have progressed after TKI therapy. (Based on HARMONi-A)
==Also known as==
*Code names: AK-112, SMT-112
*Brand name: Akeso
Category:Drugs
Category:Intravenous medications
Category:Anti-PD-1-VEGF bispecific antibodies
Category:Non-small cell lung cancer medications
Category:NMPA approved in 2024